Business Description
AnaptysBio Inc
NAICS : 325412
SIC : 2834
ISIN : US0327241065
Compare
Compare
Traded in other countries / regions
AN6.GermanyANAB.Mexico0HFQ.UKANAB.USA IPO Date
2017-01-26Description
AnaptysBio Inc is a clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product candidates are ANB020, ANB019, and Checkpoint receptor agonists. The entity generates revenue from collaborative research and development arrangements.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 22.62 | |||||
| Equity-to-Asset | 0.35 | |||||
| Debt-to-Equity | 0.1 | |||||
| Debt-to-EBITDA | -0.17 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -0.24 | |||||
| Beneish M-Score | 1.76 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 7.2 | |||||
| 3-Year EBITDA Growth Rate | -2.1 | |||||
| 3-Year EPS without NRI Growth Rate | -8.3 | |||||
| 3-Year FCF Growth Rate | -0.3 | |||||
| 3-Year Book Growth Rate | -14.8 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 31.63 | |||||
| 9-Day RSI | 34.56 | |||||
| 14-Day RSI | 36.51 | |||||
| 6-1 Month Momentum % | -25.51 | |||||
| 12-1 Month Momentum % | 10.6 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 12.21 | |||||
| Quick Ratio | 12.21 | |||||
| Cash Ratio | 12.05 | |||||
| Days Sales Outstanding | 41.49 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.5 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -1195.45 | |||||
| Net Margin % | -1278.87 | |||||
| ROE % | -50.05 | |||||
| ROA % | -22.71 | |||||
| ROIC % | -86.81 | |||||
| ROC (Joel Greenblatt) % | -570.07 | |||||
| ROCE % | -20.11 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 49.47 | |||||
| PB Ratio | 2.64 | |||||
| Price-to-Tangible-Book | 2.64 | |||||
| EV-to-EBIT | -0.71 | |||||
| EV-to-Forward-EBIT | -0.39 | |||||
| EV-to-EBITDA | -0.72 | |||||
| EV-to-Forward-EBITDA | -0.39 | |||||
| EV-to-Revenue | 7.66 | |||||
| EV-to-Forward-Revenue | 5.88 | |||||
| EV-to-FCF | -1.06 | |||||
| Price-to-Net-Current-Asset-Value | 6.59 | |||||
| Price-to-Net-Cash | 7.15 | |||||
| Earnings Yield (Greenblatt) % | -140.85 |
Balance Sheet Breakdown
Cashflow Statement Breakdown
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ANAB
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
AnaptysBio Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 10.691 | ||
| EPS (TTM) ($) | -4.84 | ||
| Beta | -0.72 | ||
| Volatility % | 40.85 | ||
| 14-Day RSI | 36.51 | ||
| 14-Day ATR ($) | 0.99284 | ||
| 20-Day SMA ($) | 20.066 | ||
| 12-1 Month Momentum % | 10.6 | ||
| 52-Week Range ($) | 18.03 - 32.435 | ||
| Shares Outstanding (Mil) | 26.49 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
AnaptysBio Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
AnaptysBio Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
AnaptysBio Inc Frequently Asked Questions
What is AnaptysBio Inc(ANAB)'s stock price today?
The current price of ANAB is $18.65. The 52 week high of ANAB is $32.44 and 52 week low is $18.03.
When is next earnings date of AnaptysBio Inc(ANAB)?
The next earnings date of AnaptysBio Inc(ANAB) is 2023-08-08 Est..
Does AnaptysBio Inc(ANAB) pay dividends? If so, how much?
AnaptysBio Inc(ANAB) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
